News

03Jul

Atnahs Acquires Rights for Bonviva® and Bondronat®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of worldwide rights (except for Japan and the US) for Bondronat® and Bonviva® from F. Hoffmann-La Roche Limited (“Roche”). Bonviva® and Bondronat® are injectable and tablet forms of ibandronic acid used for the treatment of osteoporosis and metastatic bone disease respectively. It…

Read more

03Jan

Atnahs Acquires Kytril®

Basildon, UK. Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of Kytril® from F.Hoffmann-La Roche Limited (“Roche”). Kytril® (granisetron hydrochloride) is an injectable and oral treatment for nausea and vomiting caused by other medical treatments, such as chemotherapy or radiotherapy. It is the third acquisition by Atnahs from Roche following Naprosyn®/ Anaprox®…

Read more

03Jun

Statement Regarding Recent Media Coverage

Basildon, UK, 3 June 2016 – Atnahs Pharma is providing the following statement in relation to recent media coverage. Atnahs Pharma (“Atnahs”) is a UK registered limited company founded in 2013. The company makes and sells medicines both into the UK and internationally. Atnahs acquires the rights to make medicines from large pharmaceutical companies at…

Read more

11May

Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, May 11 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce that the Food and Drug Administration (“FDA”) has granted supplement approval to the manufacturing site transfer of Naproxen Suspension in the US. This has triggered the second and final US$ 2 million payment in a total transaction of US$4.25 million.

Read more

31Mar

Atnahs Acquires Majority Stake in Pharmanovia A/S in Denmark

Basildon, UK, March 31 2016 – Atnahs Pharma UK Limited (“Atnahs”) is pleased to announce the acquisition of a majority stake in Pharmanovia A/S (“Pharmanovia”) in Denmark. Pharmanovia is a speciality pharma business with a portfolio and accompanying pipeline of nice products.

Read more

31Jan

Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million. The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.

Read more